# GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

> **NCT00896519** · PHASE2 · UNKNOWN · sponsor: **French Innovative Leukemia Organisation** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** sargramostim
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **GENETIC:** gene expression analysis
- **GENETIC:** gene rearrangement analysis
- **GENETIC:** polymerase chain reaction
- **OTHER:** R-CHOP regimen
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00896519
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896519, "GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00896519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*